Illumina

ILMN58

$134.30arrow_drop_up2.54%$3.33

ILMN58

$134.30

arrow_drop_up2.54%$3.33

Performance History

Key Stats
Open	$130.62
Prev. Close	$130.21
EPS	-19.21
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-

PE Ratio	-

	LOW	HIGH
Day Range	129.69	134.94
52 Week Range	86.57	144.15

Ratios







EPS	-19.21

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Illumina (ILMN)

Illumina Inc (ILMN) is a leading company in the field of genomics and molecular diagnostics. With a strong focus on innovation and cutting-edge technology, Illumina has become a key player in the healthcare industry. The company's stock price history has been impressive, with steady growth over the years. Illumina's commitment to research and development has led to numerous breakthroughs in genetic sequencing and diagnostics, making it a leader in the industry. The company's dedication to improving patient outcomes and advancing precision medicine has earned it a strong reputation among healthcare professionals and investors alike. Illumina's stock quote reflects the strong market demand for its products and services. With a solid financial performance and a diverse portfolio of offerings, Illumina is well-positioned for continued success.

In addition to its strong market presence, Illumina also has a robust news presence. The company regularly announces new partnerships, product launches, and research findings, keeping investors and industry professionals informed of its latest developments. This constant stream of news helps to maintain investor confidence and showcases Illumina's ongoing commitment to innovation. Illumina's stock analysis reveals a company with strong fundamentals and a positive outlook. The company's market cap is impressive, reflecting its status as a leading player in the genomics field. Illumina's PEG ratio suggests that the stock is reasonably priced, indicating potential growth opportunities. When compared to the industry, Illumina stands out as a top performer, with a proven track record of success. The company's 52-week range demonstrates stability and consistent performance, providing investors with confidence in the stock. The day range and trading volume are also indicative of a healthy market for Illumina shares.

Websitecall_made

Sector: Healthcare
Industry: Diagnostics & Research
CEO: Mr. Francis A. deSouza
Headquarters: San Diego
Employees: 11500
Exchange: NASDAQ

Keep an eye on Illumina

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Illumina 's (ILMN) price per share?

The current price per share for Illumina (ILMN) is $134.3. The stock has seen a price change of $3.33 recently, indicating a 2.54% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Illumina (ILMN)?

For Illumina (ILMN), the 52-week high is $144.15, which is 7.34% from the current price. The 52-week low is $86.58, the current price is 55.12% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Illumina (ILMN) a growth stock?

Illumina (ILMN) has shown an average price growth of 0.41% over the past three years. It has received a score of 16 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Illumina as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Illumina (ILMN) stock price performance year to date (YTD)?

As of the latest data, Illumina (ILMN) has a year-to-date price change of -2.41%. Over the past month, the stock has experienced a price change of -1.18%. Over the last three months, the change has been 24.24%. Over the past six months, the figure is 3.2%. Looking at a longer horizon, the five-year price change stands at -55.68%.

help

Is Illumina (ILMN) a profitable company?

Illumina (ILMN) has a net income of -$1.16B, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 60.92% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 22.75% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $4.5B, although specific revenue growth data is currently not available. The gross profit is $2.74B. Operating income is noted at -$1.07B. Furthermore, the EBITDA is $219M.

help

What is the market capitalization of Illumina (ILMN)?

Illumina (ILMN) has a market capitalization of $20.74B. The average daily trading volume is 1.6M, indicating the stock's liquidity and investor engagement.